TIL Treatment Process
Efficacy of TIL treatment in solid tumours
| Patient Baseline | Indications | Therapies | Treatment | Company | ORR%1 |
| Endline treatment | (NCT0%360579 queue 2 + queue 4) | TIL | Lifileucel | lovance | 31% (2022ASco) |
| mNsCLC (NCT04614103) | TIL | LN-145 | lovance | 21.4%（2021.6.29） | |
| Cervical cancer (NCT03108495 team has 4 - not registered) | TIL | LN-145 | lovance | 44%（N=27） | |
| Frontline treatment | Black Tycoon (NCT03645928TIL+PD1 Column 1A) | TIL+PD1 | Lifileucel+pembrolizumab | lovance | 60%（2021.9.22） |
| HNscc (NCT03645928 cohort 2A) | TIL+PD1 | Lifileucel+pembrolizumab | lovance | 38.9% | |
| Cervical cancer (NCT03H)8495 cohort 3) | TIL+PD1 | Lifileucel+pembrolizumab | lovance | 57.1%（N=14）(2021.9.22) |
Patient Recruitment
You may be eligible to participate in this clinical study if you meet the following basic requirements.
1. are ≥ 18 years of age and of any gender
2. solid tumours such as AJCC (V8) stage III or IV melanoma, non-small cell lung cancer, or cervical cancer that have failed to respond to existing treatment or for which no standard treatment is available (confirmed by histology); patients have residual lesions available for surgical resection (>1.5 cm3) or biopsy puncture (>1.5 cm3) and measurable lesions after resection for TIL collection and efficacy assessment.
3. the first TIL treatment needs to be more than 2 weeks apart from the end of the previous chemotherapy, radiotherapy, targeted therapy, biotherapy, immunotherapy.
For further enquiries, please call: Liu Xi-Man | 17695804323
